FDA rejects Replimune filing

The Food and Drug Administration has again refused to clear Replimune’s melanoma therapy, saying the company still has not shown enough evidence that RP1 works. (fda.gov) A complete response letter dated April 10, 2026 said the resubmitted biologics license application for RP1, or vusolimogene oderparepvec, plus nivolumab did not meet the agency’s standard for “substantial evidence of effectiveness” in adults with unresectable advanced cutaneous melanoma after prior programmed death receptor-1 therapy. (fda.gov) The Food and Drug Administration said its new review team reanalyzed data from study RPL-001-16 and reviewed added data from study RP1-104, then unanimously concluded the package was still insufficient. The letter listed three main problems in RPL-001-16: the trial could not isolate RP1’s contribution alongside nivolumab, the patient population was heterogeneous, and response assessments were clouded by surgical interventions. (fda.gov) Cancer drug trials are supposed to show whether a treatment helps patients better than a comparison group or a credible historical benchmark. The Food and Drug Administration said Replimune relied on a single-arm Phase 2 study of 140 patients without a concurrent control or an acceptable historical control for the main endpoint, objective response rate. (fda.gov) That finding extends a dispute that first surfaced on July 22, 2025, when Replimune disclosed an initial complete response letter on the same application. At that point, the company said no safety issues had been raised, but the agency found the IGNYTE study was not an adequate, well-controlled investigation and said the mixed patient population limited interpretation. (sec.gov) Replimune had entered 2025 expecting a faster path. The Food and Drug Administration accepted the filing on January 21, 2025, granted priority review, set a July 22, 2025 action date, and noted then that it was not planning an advisory committee meeting. (sec.gov) RP1 is an oncolytic immunotherapy, a treatment built from a modified virus designed to infect tumors, kill cancer cells, and stir a broader immune response. Replimune says RP1 is based on herpes simplex virus type 1 and is engineered with granulocyte-macrophage colony-stimulating factor and a fusogenic protein, while nivolumab is an immune checkpoint blocker already used in melanoma. (sec.gov) The company’s case for approval rested on promising tumor-shrinkage data, not a randomized head-to-head win. ClinicalTrials.gov lists IGNYTE, study NCT03767348, as a multicenter, open-label Phase 1 and Phase 2 trial, and conference reports from the study have described objective response rates around 33% in anti-programmed death receptor-1-failed melanoma. (clinicaltrials.gov) (jitc.bmj.com) Replimune’s own pipeline page still says the confirmatory Phase 3 IGNYTE-3 trial in advanced melanoma is underway and enrolling. In the April 10, 2026 letter, the Food and Drug Administration said the separate RP1-104 dataset had reached only about 10% of its planned enrollment and lacked mature duration-of-response data. (replimune.com) (fda.gov) A related debate is playing out around artificial intelligence in drug development, where consultants and regulators are pressing companies to show how tools are built, checked, and monitored. ClinReg Partners said in a recent guidance note that good artificial intelligence practice in drug development rests on data quality, transparency, validation, human oversight, and lifecycle monitoring. (clinregpartners.com) For Replimune, the immediate issue is not whether RP1 generated responses, but whether the evidence package can satisfy the Food and Drug Administration’s trial-design standard. The agency’s April 10 letter says its advice to the company has been consistent since March 2021. (fda.gov)